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repeat proteins expressed in C. elegans form
aggregates as the animals age, and this aggrega-
tion is delayed in long-lived insulin/IGF-1 path-
way mutants (26). Because sHSPs are known to
inhibit protein aggregation (27), we asked
whether shsp RNAi might accelerate the onset
of polyglutamine aggregates in C. elegans. We
found that it did (Fig. 4, D and E), whereas
RNAi of the other stress-response genes we
tested did not (Fig. 4). As predicted, daf-16 or
hsf-1 RNAi accelerated aggregation formation
to an even greater extent (Fig. 4E) (28). Thus,
possibly by functioning as molecular chaper-
ones, sHSPs may influence the rates of aging
and polyglutamine aggregation coordinately. In
this model, mutations in the DAF-2 pathway
delay both aging and susceptibility to this age-
related disease, at least in part, by increasing
shsp gene expression.
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Persistent infections with hepatitis C virus (HCV ) are likely to depend on viral
inhibition of host defenses. We show that the HCV NS3/4A serine protease
blocks the phosphorylation and effector action of interferon regulatory fac-
tor–3 (IRF-3), a key cellular antiviral signaling molecule. Disruption of NS3/4A
protease function by mutation or a ketoamide peptidomimetic inhibitor re-
lieved this blockade and restored IRF-3 phosphorylation after cellular challenge
with an unrelated virus. Furthermore, dominant-negative or constitutively ac-
tive IRF-3 mutants, respectively, enhanced or suppressed HCV RNA replication
in hepatoma cells. Thus, the NS3/4A protease represents a dual therapeutic
target, the inhibition of whichmay both block viral replication and restore IRF-3
control of HCV infection.
Persistent HCV infection is a leading cause of
liver disease worldwide and is frequently re-
fractory to current interferon (IFN)-based ther-
apies (1, 2). HCV persistence is facilitated by
the ability of the virus to incorporate adaptive
mutations and to replicate as a population of
genetically distinct quasispecies (3, 4), but is
likely to result from specific disruption of host
immune responses by HCV proteins (5–7). The
HCV genome, a 9.6-kb single-stranded RNA of
Fig. 1. HCV regulation of the IRF-3 pathway. (A) Organization of the genotype 1b HCV RNA
replicating in Huh7 C5B2-3 cells (referred to as Huh7 2-3 cells) (19) and of the genotype 1a
polyprotein expressed conditionally in UHCV11 cells. The NS3/4A coding region is shaded. (B)
Immunostaining for IRF-3 in SenV-infected (SenV) or mock-infected (SenV–) cells. From top to
bottom, IRF-3 subcellular localization in control Huh7 cells, 2-3 cells, or interferon-cured 2-3c cells
is shown (20), as are UHCV11 cells with (HCV 1a) or without polyprotein expression (–HCV 1a).
On the right are immunoblots for NS3 and actin in corresponding cell extracts. (C) Huh7 cells, Huh7
2-3 cells, or 2-3c cells were transfected with the indicated promoter–luciferase reporter constructs
and then infected with SenV (black bars) or mock-infected (gray bars). Luciferase activities were
determined in cell extracts (mean  S.D. from three experiments) (20).
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positive polarity, encodes a large polyprotein
that is posttranslationally cleaved into structural
and nonstructural (NS) proteins (Fig. 1A) (8).
The NS proteins support viral RNA replication
(9) and include the NS3/4A holoenzyme com-
plex that has serine protease, adenosine triphos-
phatase (ATPase), and RNA helicase activities
(10). The NS3/4A protease catalyzes the post-
translational processing of NS proteins from the
viral polyprotein and is a prime target for the
development of new antiviral drugs.
Cellular control of virus infection is medi-
ated through a variety of processes that affect
different stages of the viral life cycle (11).
Interferon regulatory factors (IRFs) are key
transcription factors that initiate this cellular
antiviral state (12). IRF-3 is a latent cytoplas-
mic factor that is activated through phosphoryl-
ation by an undefined virus-activated kinase
(VAK). VAK is stimulated by double-stranded
RNA intermediates and other products of virus
replication (13–15). Phosphorylated IRF-3
translocates to the nucleus, where it induces
transcription of type I IFNs and other antiviral
genes (13, 16). HCV RNA replication has the
capacity to activate IRF-3 and to stimulate cel-
lular antiviral responses (17), which suggests
that control of IRF-3 could be an important
determinant of viral persistence. Indeed, IRF-
3–null mice lack resistance to challenge with
other viruses (18), and some viruses encode
proteins perturbing IRF-3 function (12, 15).
Because HCV does not grow in cultured
cells (8), we studied the IRF-3 pathway in Huh7
hepatoma cells containing an autonomously
replicating, genome-length, genotype 1b HCV
RNA (Huh7 2-3 cells) (19) and in osteosarcoma
cells that conditionally express the entire geno-
type 1a polyprotein (UHCV11 cells) (Fig. 1A).
Sendai virus (SenV) is a potent inducer of
IRF-3 activation (13) When it infects control
Huh7 cells, it induces nuclear translocation of
IRF-3, thereby demonstrating the presence of
an intact IRF-3 pathway in these cells (Fig. 1B).
However, neither endogenous replicating HCV
RNA nor SenV infection induced nuclear trans-
location of IRF-3 in Huh7 2-3 cells (Fig. 1B).
Elimination of replicating HCV RNA by prior
treatment with high concentrations of IFN-2b
(Huh7 2-3c cells) (20) restored SenV activation
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Fig. 2. The HCV NS3/4A
protein complex blocks
IRF-3 activation. (A) ISG56
promoter activities in
Huh7 cells that were co-
transfected with the ISG56
promoter–luciferase con-
struct (Fig. 1C) and various
HCV protein expression
vectors, and then infected
with SenV (black bars) or
mock-infected (gray bars).
The SenV-induced increase
in luciferase activity within
each culture was signiﬁ-
cantly different from cells
expressing NS3/4A (Stu-
dent’s t test; P  0.008).
On the right are immunoblots of HCV proteins in the corresponding cell extracts. (B)
Immunoblots (left) for IRF-3, HCV proteins, and actin in extracts of individual osteosarcoma
cell lines cultured to repress (–) or induce () expression of the HCV core, NS5A, or NS3/4A
proteins (denoted as HCV ), and then either SenV-infected or mock-infected. The arrowhead
and hatch marks denote high-mass hyperphosphorylated (virus-activated) and basally phos-
phorylated (inactive) IRF-3 isoforms, respectively. A similar analysis (right) of UHCV11 cells
conditionally expressing the entire viral polyprotein. The core protein (labeled C) and NS3,
NS5B, NS5A, and NS4B were detected by using a well-characterized patient serum (17, 20). (C)
IRF-3 subcellular localization in osteosarcoma cells conditionally expressing core, NS5A, or
NS3/4A in the presence or absence of SenV infection.
Fig. 3. The IRF-3 blockade is de-
pendent on HCV NS3/4A protease
activity and prevented by a small
molecule inhibitor of viral pro-
tease function. (A) ISG56 promot-
er activity in Huh7 cells transiently
expressing wt NS3/4A, or the
C1125A or W1528A NS3/4A mu-
tants. See Fig. 1C legend for de-
tails. (B) Immunoblots for IRF-3
(top gel) and NS3 (bottom gel) in
osteosarcoma cells that were cul-
tured to induce () or repress (–)
NS3/4A expression in the pres-
ence or absence of 20 M SCH6,
and then SenV-infected or mock-
infected. (C) Subcellular localiza-
tion of IRF-3 under the conditions
described in Fig. 3B: left, DAPI
staining of nuclei; right, FITC stain-
ing for IRF-3.
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of IRF-3 and showed that the inhibition of
IRF-3 activation was HCV-specific. IRF-3 ac-
tivation was also blocked by HCV polyprotein
expression in UHCV11 cells (Fig. 1B), which
indicates that IRF-3 function is blocked by
multiple HCV genotypes and in different cell
types, independently of HCV RNA replication.
Neither HCV RNA replication nor conditional
expression of HCV proteins inhibited SenV
infection (21).
IRF-3 transcriptionally activates the promot-
ers for the IFN-, IFN-stimulated genes ISG56
and ISG15, and RANTES genes (22). We found
each promoter to be induced efficiently in con-
trol Huh7 cells upon SenV infection (Fig. 1C).
In contrast, SenV induction of promoter activity
was blocked in Huh7 2-3 cells containing rep-
licating HCV RNA, but fully restored in inter-
feron-cured Huh7 2-3c cells. Thus, disruption of
the IRF-3 pathway by one or more HCV pro-
teins blocks expression of IRF-3–activated
genes. Although transient expression of the
HCV core-E1-E2-p7, NS4B, NS4AB, NS5A or
NS5B proteins did not affect SenV induction of
the ISG56 promoter in Huh7 cells, expression of
the NS3/4A complex strongly inhibited promot-
er induction (Fig. 2A), which suggested that it
was responsible for perturbation of IRF-3 func-
tion. Because the stability, subcellular local-
ization, and function of NS3 depend on non-
covalent association with NS4A (10), we as-
sessed the inhibitory activity of NS3 and
NS4A individually. Neither protein expressed
alone substantially impaired induction of the
ISG56 promoter (Fig. 2A). Further experi-
ments in osteosarcoma cells demonstrated that
NS3/4A disrupts IRF-3 function by blocking
both accumulation of the hyperphosphory-
lated IRF-3 isoform (Fig. 2B) and the nuclear
translocation of IRF-3 (Fig. 2C) resulting
from viral induction of VAK (23).
To determine whether the enzymatic activi-
ties or RNA binding properties of NS3/4A are
required for disruption of IRF-3 activation, we
introduced single–amino acid substitutions into
NS3 that eliminated the RNA binding and heli-
case functions [replacing Trp1528 with Ala
(W1528A)] (24) or its serine protease activity
[replacing Cys1125 with Ala (C1125A)] (10, 20).
The NS3/4A complex containing the C1125A
mutation lacked protease activity when ex-
pressed in Huh7 cells (21) and failed to block
SenV induction of the IRF-3–dependent ISG56
promoter (Fig. 3A). In contrast, the W1528A
mutant retained the ability to block IRF-3 acti-
vation (Fig. 3A). Because these results suggest
that the serine protease activity of NS3 is re-
sponsible for perturbation of the IRF-3 pathway,
we assessed the ability of SCH6, one of a class
of recently described specific peptidomimetic
ketoamide inhibitors of the NS3/4A serine pro-
tease (25), to reverse the NS3/4A inhibition of
SenV-induced IRF-3 phosphorylation. The an-
tiviral activity of SCH6 eliminated detectable
HCV proteins and caused profound reductions
in viral RNA abundance when the compound
was added to cultures of Huh7 2-3 cells for 5 to
7 days (21). Consistent with its ability to inhibit
the NS3/4A protease, SCH6 blocked cis-cleav-
age of the NS3/4A precursor protein in osteo-
sarcoma cells (Fig. 3B). SCH6 also rescued
SenV-induced IRF-3 phosphorylation and
IRF-3 nuclear translocation in these cells (Fig. 3,
B and C). These data provide strong evidence
that the NS3/4A serine protease activity is re-
quired for blockade of the IRF-3 pathway and
that this blockade can be reversed by antiviral
inhibitors of protease activity. We confirmed
this directly by demonstrating the appearance of
phosphorylated IRF-3 in Huh7 2-3 cells after
treatment with SCH6 (21).
To further define the relationship between
HCV replication and IRF-3, we characterized
IRF-3 activation status and viral RNA replica-
tion in cells containing subgenomic HCV RNA
replicons constructed from the wild-type Con1
HCV sequence (20). Wild-type Con1 RNA rep-
licates poorly in Huh7 cells but accumulates
adaptive mutations in the NS proteins that vari-
ably enhance its replication capacity (9, 19, 26).
One replicon, HP, exhibited robust replication
and blocked both basal and SenV-induced
IRF-3 phosphorylation, nuclear translocation,
Fig. 4. The IRF-3 pathway regulates HCV
RNA replication. IRF-3 localization, expres-
sion, and HCV RNA replication in normal
Huh7 cells or Huh7 cells harboring HP or
A7 subgenomic replicons. (A) IRF-3 local-
ization (top) and protein expression (mid-
dle) within mock-infected or SenV-infected
cells. (Bottom) IRF-3 localization within HP
replicon cells after transient expression of
the IRF-3 5D mutant (20, 26). (B) IFN-, ISG15, ISG56, or RANTES promoter activities in replicon
cells infected with SenV. See legend of Fig. 1C for details. (C) NS5A, IRF-3, ISG56, and ISG15 protein
expression in normal Huh7 cells (lane 1) or A7 (left gel) and HP replicon cells (right gel) after
transfection with 1 g of vector control, or 0.5 or 1 g of IRF-3 5D or IRF-3 N expression
plasmids, as indicated. Bands representing endogenous IRF-3, and 5D and N mutants are marked.
Lane 3 in each gel shows protein levels in control cultures treated for 24 hours with 10 U/ml of
IFN-2a. (Bottom) Northern blots of HCV (upper) and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) RNAs (lower) present in control Huh7 cells (lane 5), or A7 (lanes 6 to 10) and HP (lanes
11 to 15) replicon cells transfected with IRF-3 expression plasmids as indicated. Values below each
lane indicate viral RNA abundance relative to the vector control.
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and IRF-3–dependent promoter activity (Fig.
4). Inhibition of nuclear translocation was not
due to a global defect in transport, because a
constitutively active, phospho-mimetic IRF-3
mutant, 5D (27), efficiently localized to the
nucleus when expressed in these cells (Fig. 4A,
bottom). A second Con1 replicon, A7, replicat-
ed poorly. A7 replicon cells had only 1/10th the
viral RNA abundance of HP cells, and they
displayed a low basal level of nuclear localized,
hyperphosphorylated IRF-3 and IRF-3–depen-
dent promoter activity that was further respon-
sive to SenV challenge (Fig. 4, A and B). These
results show that HCV replication has the po-
tential to both activate and block the IRF-3
pathway.
The basal activation of IRF-3 in A7 cells
correlated with expression of the IRF-3–de-
pendent genes ISG56 and ISG15 (Fig. 4C)
(22). Transient expression of the constitutive-
ly active IRF-3 5D mutant (27) in these cells
further increased ISG15 and ISG56 expres-
sion and caused a modest reduction in repli-
con abundance. In contrast, expression of a
dominant-negative IRF-3 mutant, N (27),
resulted in a 500% increase in HCV RNA
levels and a parallel reduction in IRF-3 target
gene expression. Thus, disruption of the
IRF-3 pathway enhances HCV RNA replica-
tion, which may explain the higher basal
abundance of HCV RNA in HP than in A7
cells (Fig. 4C, bottom, compare lanes 6 and
11). Although expression of the constitutive-
ly active 5D mutant induced IRF-3 target
gene expression and reduced replicon abun-
dance in HP cells, expression of the domi-
nant-negative N mutant had no effect in
these cells because of the preexisting block in
the IRF-3 pathway imposed by NS3/4A.
Our results show that HCV interacts directly
with host pathway(s) that signal IRF-3 activa-
tion and that HCV, like other viruses (28), has
evolved a specific mechanism to circumvent a
major arm of the host’s immune response. Ac-
tivated IRF-3 suppresses HCV RNA replica-
tion, whereas viral RNA abundance is increased
when IRF-3 function is disrupted. These find-
ings make the activation status of IRF-3 an
important factor in the virus–host cell interac-
tion. The inhibition of IRF-3 activation by the
NS3/4A protease likely involves perturbation
of cellular processes that catalyze or otherwise
trigger IRF-3 phosphorylation (27). Although
the VAK responsible for phosphorylation of
IRF-3 in this context has yet to be identified,
our results suggest that one or more signaling
components in the IRF-3 activation pathway,
including possibly the VAK itself, could be
specifically targeted for proteolysis by NS3/4A.
The regulatory factor IRF-3 induces ex-
pression of a variety of cellular genes in-
cluding the type I IFNs (14, 29), which
contribute to and further amplify the anti-
viral response by inducing hundreds of
IFN-stimulated genes (11, 28). Inhibition
of IRF-3 activation may not only promote
viral persistence after initial infection, but
also may reduce the effectiveness of inter-
feron therapies, because many IFN-stimu-
lated genes contain IRF-3 target sites with-
in their promoter/enhancer regions (22, 29).
Our results with SCH6 suggest that candi-
date antivirals that target the HCV pro-
tease, while blocking viral replication by
interfering with processing of the polypro-
tein, may also restore the responsiveness of
the IRF-3 pathway. Such “dual efficacy”
should be considered in evaluating protease
inhibitors destined for future clinical trials.
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Triggering the Interferon
Antiviral Response Through an
IKK-Related Pathway
Sonia Sharma,* Benjamin R. tenOever,* Nathalie Grandvaux,*
Guo-Ping Zhou, Rongtuan Lin,† John Hiscott†
Rapid induction of type I interferon expression, a central event in establishing
the innate antiviral response, requires cooperative activation of numerous
transcription factors. Although signaling pathways that activate the transcrip-
tion factors nuclear factor B and ATF-2/c-Jun have been well characterized,
activation of the interferon regulatory factors IRF-3 and IRF-7 has remained a
critical missing link in understanding interferon signaling. We report here that
the IB kinase (IKK)–related kinases IKKε and TANK-binding kinase 1 are com-
ponents of the virus-activated kinase that phosphorylate IRF-3 and IRF-7. These
studies illustrate an essential role for an IKK-related kinase pathway in trig-
gering the host antiviral response to viral infection.
The success of host cell defense against viral
infection depends on detection of the invad-
ing pathogen. Upon recognizing viral anti-
gens, the cell activates a multitude of signal-
ing cascades to produce cytokines that both
impede pathogen replication and stimulate
immune responses (1–3). Interferons (IFNs)
are well-characterized components of the in-
nate host defense, and rapid induction of IFN
expression in response to viral infection re-
quires posttranslational modification of tran-
scription factors, including nuclear factor B
(NF-B), ATF-2/c-Jun, and interferon regu-
latory factors (IRFs) IRF-3 and IRF-7 (4, 5).
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